In Silico药物发现市场规模、份额、按产品、工作流程、标靶治疗领域、最终用户和地区分類的成长分析 - 产业预测，2025 年至 2032 年

2023 年全球In Silico药物发现市场规模价值 29 亿美元，预计将从 2024 年的 32.2 亿美元增长到 2032 年的 74.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 11.0%。

由于药物发现资料量的增加和生物资讯技术的进步，预计 2023 年至 2030 年间In Silico药物发现市场将大幅成长。市场正在利用In Silico策略来识别药物目标、开发候选分子并优化结合特性。以降低再入院率和医疗错误为重点的生物标记识别的增加预计将进一步推动市场扩张。计算生物学的重大进步和In Silico设计服务正在使市场变得更具吸引力。然而，价格压力和开放原始码软体的可用性等挑战可能会阻碍成长。总体而言，製药公司的药物发现计划和研究活动的激增为市场相关人员创造了巨大的商机。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

In Silico药物发现市场按产品分類的规模

• 市场概况
• 软体即服务
• 软体
• 咨询即服务

In Silico药物发现市场规模（按工作流程）

• 市场概况
• 临床前试验
• 发现
• 临床试验

In Silico药物发现市场规模（按标靶治疗领域划分）

• 市场概况
• 代谢紊乱
• HIV
• 感染疾病
• 肌肉骨骼疾病
• 精神障碍
• 神经系统疾病
• 肿瘤疾病

In Silico药物发现市场规模（按最终用户划分）

• 市场概况
• 合约研究组织
• 製药和生物製药公司
• 学术研究所
• 其他的

In Silico药物发现市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Atomwise（USA）
• Insilico Medicine（Hong Kong）
• Iktos（France）
• Cradle（USA）
• BenevolentAI（UK）
• Schrodinger（USA）
• Cloud Pharmaceuticals（USA）
• Numerate（USA）
• XtalPi（China）
• BenevolentAI（UK）
• Biovista（USA）
• Certara（USA）
• Cloud Pharmaceuticals（USA）
• XtalPi（China）
• Atomwise（USA）
• Exscientia（UK）
• Insilico Medicine（Hong Kong）
• Iktos（France）
• Cradle（USA）

结论和建议

Global Insilico Drug Discovery Market size was valued at USD 2.9 billion in 2023 and is poised to grow from USD 3.22 billion in 2024 to USD 7.42 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The in-silico drug discovery market is poised for significant growth from 2023 to 2030, driven by the increasing volume of drug discovery data and advancements in bioinformatics technologies. This market leverages in-silico strategies to identify drug targets, develop candidate molecules, and optimize their binding properties. The projected rise in biomarker identification, coupled with a focus on minimizing readmission rates and medical errors, further supports market expansion. Significant advancements in computational biology and cost-effective in-silico designing services enhance market appeal. However, challenges such as pricing pressures and the availability of open-source software may hinder growth. Overall, the surge in drug discovery projects and research activity within pharmaceutical organizations presents considerable opportunities for market players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insilico Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insilico Drug Discovery Market Segmental Analysis

Global Insilico Drug Discovery Market is segmented by Product, Workflow, Target Therapeutic Area, End User and region. Based on Product, the market is segmented into Software-as-a-Service, Software and Consultancy-as-a-Service. Based on Workflow, the market is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. Based on Target Therapeutic Area, the market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. Based on End User, the market is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insilico Drug Discovery Market

The global in-silico drug discovery market is expected to experience significant growth in the coming years, primarily driven by advancements in biomarker identification. Additionally, there is a growing emphasis on reducing readmission rates and minimizing medical errors, which further fuels this demand. Innovations in computational technologies within computational biology and enhancements in in-silico drug discovery methodologies also contribute substantially to market expansion. These factors collectively create a robust environment that encourages the adoption of in-silico approaches, ultimately transforming the drug discovery landscape and meeting the evolving needs of the healthcare sector.

Restraints in the Global Insilico Drug Discovery Market

A significant challenge facing the Global Insilico Drug Discovery market is its inherently short lifespan, which serves as a primary restraint. The analysis durations for this technology can vary from tens to hundreds of nanoseconds, contingent upon the complexity of the systems being evaluated and the computational resources available. This brevity poses a substantial issue, as the time frames-ranging from a few milliseconds to several seconds-are often insufficient for precise predictions of protein folding. Consequently, this limitation may hinder the sampling of an adequate number of protein conformations, potentially impacting the accuracy and reliability of drug discovery outcomes.

Market Trends of the Global Insilico Drug Discovery Market

The global in-silico drug discovery market is witnessing significant growth, primarily fueled by the rising adoption of cloud-based solutions that enhance computational capabilities for pharmaceutical researchers. This trend allows for scalable and adaptive computing environments, empowering researchers with virtually unlimited processing power to accelerate drug development processes. Notably, platforms like BT's Cloud Compute life sciences service offer tailored applications that cater to various stages of the drug discovery value chain, enabling seamless compatibility across diverse pipelines. As companies increasingly prioritize tailored solutions, the market is set to expand, driving innovation and efficiency in drug discovery efforts.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Insilico Drug Discovery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Software-as-a-Service
• Software
• Consultancy-as-a-Service

Global Insilico Drug Discovery Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Pre-Clinical Tests
• Discovery
• Clinical Tests

Global Insilico Drug Discovery Market Size by Target Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Metabolic disorders
• HIV
• Infectious diseases
• Musculoskeletal disorders
• Mental disorders
• Neurological disorders
• Oncological disorders

Global Insilico Drug Discovery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Contract Research Organizations
• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

Global Insilico Drug Discovery Market Size & CAGR (2025-2032)

• North America (Product, Workflow, Target Therapeutic Area, End User)
  • US
  • Canada
• Europe (Product, Workflow, Target Therapeutic Area, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Workflow, Target Therapeutic Area, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Workflow, Target Therapeutic Area, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Workflow, Target Therapeutic Area, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Atomwise (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iktos (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cradle (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Schrodinger (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cloud Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numerate (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XtalPi (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovista (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Certara (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cloud Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XtalPi (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atomwise (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exscientia (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iktos (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cradle (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations